Symptoms breakthrough

Nevertheless, although the nonsedating H antihistamines have substantially improved the acceptabiUty and clinical efficacy of this class of compounds, these do not provide complete rehef eye disease responds less well than nasal disease, of the rhinitis symptoms nasal congestion responds poorly, breakthrough symptoms occur at high poUen counts, and only some 70% of patients report excellent to good treatment responses. Considerable research therefore still continues in the H antihistamine field. New antihistamines are continually being introduced. 

Alprazolam and clonazepam are the most frequently used of the BZs and are well accepted by patients. Therapeutic response typically occurs in 1 to 2 weeks. With alprazolam, the duration of action may be as little as 4 to 6 hours with breakthrough symptoms between dosing. The use of extended-release alprazolam or clonazepam avoids this problem. 

Evidence also supports a clinically significant rebound-withdrawal phenomena between doses of alprazolam, sometimes referred to as interdose or breakthrough symptoms (233, 234). Mellor and Jain (218) raised the possibility that some long-term diazepam users may be subject to a similar phenomenon ... 

For example carbamazepine is both a substrate and an inducer of 3A4. Thus as treatment becomes chronic, 3A4 is induced and carbamazepine blood levels fall (Fig. 6—19)- Failure to recognize this effect and to increase carbamazepine dosage to compensate for it may lead to a failure of anticonvulsant or mood-stabilizing efficacy, with breakthrough symptoms. 

Alprazolam XR may be dosed less frequently than immediate release alprazolam, and lead to less inter-dose breakthrough symptoms and less clockwatching in anxious patients... 

Cetirizine (t 7 h), loratadine (t15 h) and terfenadine (t20 h) are effective taken once daily and are suitable for general use. Acrivastine (t)/ 2 h) is so short acting that it is best reserved for intermittent therapy, e.g. when breakthrough symptoms occur in a patient using topical therapy for hay fever. Other nonsedating antihistamines are desloratadine, fexofenadine, levocetirazine and mizolastine. 

The time range that subjects spent in the subtherapeutic range or time at risk, in hours, which is essentially the duration of time where subjects might be at risk of breakthrough symptoms. 

Dosing and Administration. The starting dose of clonazepam is 0.25 mg twice a day, with an increase to 1 mg by the third day of therapy. Further increases of dose (by 0.25 or 0.5 mg) every 3 days to 4 mg/day can be made if needed. The starting dose of alprazolam is 0.25 to 0.5 mg three times daily (or 0.5 mg once a day of alprazolam extended-release ), slowly increasing over several weeks to reach an ideal dose. The duration of action may be as little as 4 to 6 hours with resulting breakthrough symptoms use of the extended-release alprazolam or clonazepam will avoid this problem. Most patients require 3 to 6 mg/day of alprazolam, and some need doses of 6 to 10 mg/ day to obtain a full therapeutic (antipanic and antiphobic) response. 

Monitor the patient for a reduction in vasomotor symptoms, vaginal dryness, and improvement in sleep. Also monitor for breakthrough bleeding and spotting, adverse effects of HRT, and improvement in QOL. 

Suppressive therapy is effective for controlling all symptoms related to the disease and may impact troublesome complications of infection. Before beginning suppressive therapy, discuss patient expectations. Encourage patients to record any breakthrough episodes, as this may require treatment re-evaluation and adjustment. 

Many symptoms occurring in the first cycle of OC use (e.g., breakthrough bleeding, nausea, bloating), improve by the second or third cycle of use. 

A breakthrough in the treatment of major depression was the discovery of fluoxetine, marketed as Prozac. Fluoxetine has a mechanism of action similar to that of imipramine with an important exception. It is a selective serotonin reuptake inhibitor, an SSRI. This strongly suggests that, in some sense, the symptoms of major depression result from a deficit in serotonin specifically. By inhibiting its reuptake from the synapse, the activity of serotonin is enhanced. Two other important drugs for major depression, sertraline (Zoloft) and paroxetine (Paxil), among several others,... 

When used for detoxification, phenobarbital is given in equal doses four times a day. The maximum daily dose of phenobarbital is 600 mg, but much lower doses are usually sufficient. The phenobarbital dose is lowered (i.e., tapered) by about 20% per day. If the patient is too drowsy, then a dose should be skipped. If breakthrough withdrawal symptoms continue to occur, then the pace of the detoxification should be slowed. Before using phenobarbital, liver function tests should be obtained. All barbiturates depend greatly on the liver to be metabolized. Alcoholics with cirrhosis or other forms of liver impairment may have difficulty clearing phenobarbital. Phenobarbital should not be used in patients with poor liver function. In addition, the barbiturates can worsen a medical condition known as porphyria and should be avoided in those with this disorder. Phenobarbital, as noted, is seldom used today for alcohol detoxification. 

Again there are relatively few studies that have investigated the use of carbamazepine in maintenance therapy. The results of the studies published suggest that carbamazepine is not as effective as lithium or divalproex. In the controlled studies of carbamazepine, the majority of patients required adjunctive treatment to prevent a breakthrough for the manic or depressive symptoms. 

The year 1979 was also the year of the first true breakthrough of the imino sugars. This was initiated by a medical researcher with Bayer company, Dr. W. Puls, who suggested a novel therapeutic concept for the treatment of diabetes type 2 symptoms after carbohydrate uptake this involved the inhibition of intestinal a-glucosidases with various compounds found in fermentation broths, among them 1,5-dideoxy-... 

Because there are also some data that concurrent use of antidepressants can lead to rapid cycling in vulnerable patients, these agents may best be cautiously used on an as-needed basis or as adjuncts when there are early signs of breakthrough depressive, psychotic, or anxious symptoms. In particular, antidepressants do not prevent manic episodes, and may even precipitate them. The fact that many patients on antidepressants experience a manic phase, however, could be coincidental, rather than drug-induced. To definitively answer this question, we need to show that the number who switch to mania is higher on, as opposed to off, antidepressant therapy. Given these concerns, however, we advocate the initial use of a mood stabilizer alone to lessen the chance of a switch to mania in bipolar depressed patients. If this is insufficient, a mood stabilizer should be used concurrently with an antidepressant. 

An important breakthrough in the development of novel neuroleptics arose over 25 years ago with the discovery of the dibenzazepine neuroleptic clozapine. This neuroleptic was novel because it attenuated both the positive and negative symptoms of schizophrenia without causing extrapyramidal side effects or elevating serum prolactin concentrations, effects which characterize most typical neuroleptics such as chlorpromazine and haloperidol. 

Neurologic adverse effects of lithium include reduced reactivity, lack of spontaneity, intellectual insufficiency, memory problems, difficulty in concentration, dysphoria. Some of these effects may be related to the therapeutic action of lithium in reducing hypomania. However, hypothyroidism, weakness and fatigue due to hypercalcemia, and breakthrough depression must be considered in the presence of these symptoms. 

---